Pacific Heights Asset Management’s Quince Therapeutics QNCX Stock Holding History

Pacific Heights Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,625	Closed	-$432K	–	79
2022 Q3	$432K	Hold	1,625	–	–	0.05%	80
2022 Q2	$721K	Hold	1,625	–	–	0.07%	83
2022 Q1	$2.01M	Hold	1,625	–	–	0.17%	81
2021 Q4	$4.1M	Buy	1,625 +250	+18%	+$1.53M	0.35%	73
2021 Q3	$25.2M	Hold	1,375	–	–	2.39%	6
2021 Q2	$14.6M	Hold	1,375	–	–	1.33%	19
2021 Q1	$9.91M	Buy	1,375 +250	+22%	+$1.8M	0.91%	36
2020 Q4	$6.25M	Hold	1,125	–	–	0.62%	52
2020 Q3	$11.3M	Buy	1,125 +310	+38%	+$2.82M	1.46%	23
2020 Q2	$7.55M	Buy	815 +240	+42%	+$2.2M	1.13%	26
2020 Q1	$5.73M	Buy	+575	New	+$5.68M	0.96%	36

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pacific Heights Asset Management's QNCX Position: Q4 2022 in Review

Pacific Heights Asset Management sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 1,625 shares — an estimated $432K sold.

Pacific Heights Asset Management first reported a position in QNCX in Q1 2020 and held it in 11 quarters. The position peaked at $25.2M in Q3 2021. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

Pacific Heights Asset Management reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
Pacific Heights Asset Management sold 1,625 Quince Therapeutics shares in Q4 2022, an estimated $432K.
Pacific Heights Asset Management first reported a position in Quince Therapeutics in Q1 2020 and held it in 11 quarters.
Pacific Heights Asset Management's Quince Therapeutics position peaked at $25.2M in Q3 2021.
48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Pacific Heights Asset Management's 13F filing for Q4 2022, filed 10 Feb 2023.